Background:

Resistance of staphylococci to b-lactams, quinolones and other agents is increasing and recently VISA as well as VRSA strains have been reported.

Objective:

NVP-PDF713 is a new peptide deformylase inhibitor active against a wide variety of Gram-positive and -negative bacteria. The current study examines the activity of NVP-PDF713 compared with those of ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, vancomycin, teicoplanin, linezolid, ranbezolid, daptomycin, oritavancin and quinupristin/dalfopristin against 131 S. aureus (62 methicillin resistant) and 127 coagulase-negative staphylococci (60 methicillin resistant).

Methods:

Microdilution using frozen trays containing cation-adjusted Mueller–Hinton broth and inocula of 1 × 105 CFU/mL with trays incubated in air.

Results:

MIC₅₀ and MIC₉₀ values (mg/mL) were as seen in the following table.

NVP-PDF713 was equally active against all staphylococcal strains (MICs <0.06–4 mg/mL), irrespective of susceptibility to other agents. Quinolone resistance was mainly seen in methicillin R strains. Vancomycin, linezolid, ranbezolid, daptomycin, oritavancin and quinupristin/dalfopristin were all active at MICs <4.0 mg/mL and teicoplanin was less active against coagulase-negative strains.

Conclusions:

NVP-PDF713, a new peptide deformylase inhibitor, was active in vitro against staphylococci.